Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 52

The percent change in hip BMD (relative to baseline) at Week 52

Time frame: Baseline and Week 52

Percent Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at Week 52

Percent change in femoral neck BMD (relative to baseline) at Week 52

Time frame: Baseline and Week 52

Percent Change From Baseline in Trochanter Bone Mineral Density (BMD) at Week 52

Percent change in trochanter BMD (relative to baseline) at Week 52

Time frame: Baseline and Week 52

Change From Baseline in Serum Calcium Levels at Week 52

Change in serum calcium value (relative to baseline) at Week 52

Time frame: Baseline and Week 52

Percent Change From Baseline in Serum Bone Markers at Week 26

Percent change from baseline at Week 26

Time frame: Baseline and Week 26

Number of Subjects With at Least 1 Treatment-emergent Adverse Event

To assess safety and tolerability, the number of subjects in each treatment group who had one or more adverse events recorded after the beginning of study drug administration were determined.

Time frame: 1 year